Key result
Smoking cessation without substitutes linked to ~48% lower odds of cardiovascular events vs. substitute-assisted quitting.
Why the study?
Although varenicline, electronic cigarettes, and heat-not-burn tobacco products have been encouraged to achieve smoking cessation, their comparative effects on cardiovascular outcomes needed investigation.
Cohort (n=374)
Open-label
Yes
Answers are grounded in this paper and cite their sources.
Should not yet change cessation aid prescribing given low-level evidence; leaves open whether residual confounding explains the higher cardiovascular risk observed with pharmacotherapy and nicotine alternatives.
Background: Recently, in order to achieve smoking cessation, the use of either varenicline substitute either electronic cigarette (e-cigarette) or heat-not-burn tobacco products (HnBP) has been encouraged.The aim of this study was to investigate the effect of smoking cessation on cardiovascular outcome comparing among e-cigarette, HnBP and varenicline substitution.Methods: 374 consecutive patients were followed up for 1 year and divided in 4 groups; a) patients who stopped smoking overall, b) patients who changed smoking with e-cigarette, c) patients who changed smoking with an HnBP, d) patients who stopped smoking and followed varenicline administration.Patient surveillance process included 4 visits per year.Results: There was a significant association between cardiovascular event and type of smoking cessation (without substitute vs. all types of substitutes).Those who experienced smoking cessation without substitute reduced the odds of having an event by 47.6% (Odds Ratio: .524,p:0.012, 95% Confidence Interval: .316,.868)compared with those using current types of cessation agents (varenicline, IQOS, e-cigarette).A statistically significant association was found between cardiovascular disease (CVD) history and event in the whole sample (p<0.001),since the events were far more frequent in those with CVD history (88.6%) than in those without CVD history (28.9%). Conclusions:The incidence of cardiovascular events in humans during 1-year follow-up of smoking cessation using varenicline or e-cigarette or HnBP, is significant higher compared with smoking discontinuation without any substitute.This finding is particularly profound in people with pre-existing coronary artery disease, highlighting a serious advisory notice for smoking cessation substitutes.
No takes yet. Share an insight, caveat, or question.
Peggy Kostakou (2022) conducted a cohort in Smoking cessation in heavy smokers (70% with stable 1-vessel coronary artery disease) (n=374). Smoking cessation without substitute vs. Smoking cessation with substitutes (varenicline, IQOS heat-not-burn tobacco product, or e-cigarette) was evaluated on Major adverse cardiovascular events (myocardial infarction and/or need for revascularization) (OR 0.524, 95% CI 0.316-0.868, p=0.012). Smoking cessation without substitutes reduced the odds of cardiovascular events by 47.6% at 1 year compared to using varenicline, IQOS, or e-cigarettes.
Synapse has enriched 10 related papers. Consider them for comparative context: